MedTrace Logo

Sertraline Effect in Uremic Pruritis

NCT05341843 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-12-14

No results posted yet for this study

Summary

This study aims to assess the effect of sertraline on uremic pruritis in patients undergoing regular haemodialysis.

Conditions

  • Uremic Pruritis

Interventions

DRUG

sertraline

sertraline at the intended dose of 50 mg twice daily for 8 weeks.

DRUG

placebo

a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mohamed Mamdouh Elsayed, MD · lecturer

  • Sherif aziz Zaki, MD · professor

  • Iman ezzat El Gohary, MD · professor

  • Heidi Hesham Abd El Hamid, MBBCh · Resident

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-09-01
Completion
2022-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05341843 on ClinicalTrials.gov